Journal
MOLECULAR PSYCHIATRY
Volume 27, Issue 7, Pages 2940-2949Publisher
SPRINGERNATURE
DOI: 10.1038/s41380-022-01565-z
Keywords
-
Funding
- Key Laboratory of Alzheimer's Disease Of Zhejiang Province
- Canadian Institutes of Health Research (CIHR) [PJT-166127]
- National Natural Science Foundation of China [81801091]
- Natural Science Foundation of Shandong Province of China [ZR2019BH076]
- UBC Four Year Fellowship
- Jock & Irene Graham Brain Research Endowment
Ask authors/readers for more resources
Alzheimer's disease is a neurodegenerative disorder that severely impairs memory and cognition. It is characterized by Aβ deposition, tau tangles, synaptic abnormalities, and dysfunctions. Targeting the synapse and early treatment windows hold promise for finding effective treatments for AD patients.
Alzheimer's disease (AD) is a neurodegenerative disorder with devastating symptoms, including memory impairments and cognitive deficits. Hallmarks of AD pathology are amyloid-beta (A beta) deposition forming neuritic plaques and neurofibrillary tangles (NFTs). For many years, AD drug development has mainly focused on directly targeting the A beta aggregation or the formation of tau tangles, but this disease has no cure so far. Other common characteristics of AD are synaptic abnormalities and dysfunctions such as synaptic damage, synaptic loss, and structural changes in the synapse. Those anomalies happen in the early stages of the disease before behavioural symptoms have occurred. Therefore, better understanding the mechanisms underlying the synaptic dysfunction found in AD and targeting the synapse, especially using early treatment windows, can lead to finding novel and more effective treatments that could improve the lives of AD patients. Researchers have recently started developing different disease-modifying treatments targeting the synapse to rescue and prevent synaptic dysfunction in AD. The main objectives of these new strategies are to halt synaptic loss, strengthen synaptic connections, and improve synaptic density, potentially leading to the rescue or prevention of cognitive impairments. This article aims to address the mechanisms of synaptic degeneration in AD and discuss current strategies that focus on the synapse for AD therapy. Alzheimer's disease (AD) is a neurodegenerative disorder that significantly impairs memory and causes cognitive and behavioural deficits. Scientists worldwide have tried to find a treatment that can reverse or rescue AD symptoms, but there is no cure so far. One prominent characteristic of AD is the brain atrophy caused by significant synaptic loss and overall neuronal damage, which starts at the early stages of the disease before other AD hallmarks such as neuritic plaques and NFTs. The present review addresses the underlying mechanisms behind synaptic loss and dysfunction in AD and discusses potential strategies that target the synapse.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available